APA (7th ed.) Citation

SH, X., LT, Y., H, Z., ZL, T., ZW, L., Y, C., . . . MQ, K. (2024). Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: A multi-center propensity score match study. Frontiers in immunology, 15, 1332492. https://doi.org/10.3389/fimmu.2024.1332492

Chicago Style (17th ed.) Citation

SH, Xie, et al. "Adjuvant Therapy Provides No Additional Recurrence-free Benefit for Esophageal Squamous Cell Carcinoma Patients After Neoadjuvant Chemoimmunotherapy and Surgery: A Multi-center Propensity Score Match Study." Frontiers in Immunology 15 (2024): 1332492. https://doi.org/10.3389/fimmu.2024.1332492.

MLA (9th ed.) Citation

SH, Xie, et al. "Adjuvant Therapy Provides No Additional Recurrence-free Benefit for Esophageal Squamous Cell Carcinoma Patients After Neoadjuvant Chemoimmunotherapy and Surgery: A Multi-center Propensity Score Match Study." Frontiers in Immunology, vol. 15, 2024, p. 1332492, https://doi.org/10.3389/fimmu.2024.1332492.